Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial.

Name: Αlpha¹ Rigor Record — Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial.
Item: Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial.
Rating: 96
Author: Αlpha¹

Cheng Y, Chen J, Zhang W, Xie C, Hu Q, Zhou N, Huang C, Wei S, Sun H, Li X, Yu Y, Lai J, Yang H, Fang H, Chen H, Zhang P, Gu K, Wang Q, Shi J, Yi T, Xu X, Ye X, Wang D, Xie C, Liu C, Zheng Y, Lin D, Zhuang W, Lu P, Yu G, Li J, Gu Y, Li B, Wu R, Jiang O, Wang Z, Wu G, Lin H, Zhong D, Xu Y, Shu Y, Wu D, Chen X, Wang J, Wang M, Yang R

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 2.75★ (Weak), 0 critical, 2 high issues for “Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 16, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

2.75 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×4−2★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Problems surfaced3 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Data authenticity concerns1

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Other integrity concernAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a rigorously designed and reported phase 3 randomized controlled trial with strong methodology: comprehensive blinding, adequate power, detailed statistical methods, and transparent reporting of outcomes and limitations. The main weakness is the vague data availability statement, which lacks a concrete access mechanism for de-identified data, and several minor copyedit issues including an incomplete sentence and a percentage typo.

Both reviewers independently scored all eight dimensions and agreed on every status; no divergence required reconciliation. The statistics verification covered only 4 recomputable tests (all consistent), so the broader statistical claims remain unverified. The integrity check flagged retrospective registration (submitted 2020-01-16 after study start 2020-01) as a medium concern, which is a transparency caveat rather than a rigor failure.

4 major claims checked against the paper's own evidence: all adequately supported.

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Recomputed 4 tests: 4 consistent, 0 inconsistent; 4 via agent-written checks.

4 integrity concerns flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 warn

The introduction cites four prior phase 3 trials (IMpower133, CASPIAN, CAPSTONE-1, ASTRUM-005) and discusses the failure of TIGIT inhibitors, establishing the premise. The rationale for combining anlotinib with PD-L1 inhibition is supported by preclinical and phase 1b data. Limitations of prior work are implicitly addressed by the trial design, though not explicitly framed as such.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The study clearly establishes its scientific foundation by citing prior randomized trials and providing a logical rationale for combining anti-angiogenesis with immunochemotherapy.

Evidence

direct quote[Introduction, paragraph 1]

“four randomized, controlled phase 3 studies (IMpower133, CASPIAN, CAPSTONE-1 and ASTRUM-005) have reported significant improvements in median OS on the order of 2–4 months”